No abuse of a dominant position by AstraZeneca
As it has not sufficiently been determined in this case that AstraZeneca enjoyed a dominant position, no violation of the Dutch Competition Act has been established. It could not be established that a sufficiently substantial group of patients that were prescribed the expensive branded drug Nexium outside of hospitals could also have benefited from a cheaper, generic version of the drug.
Documents
We do our utmost to make our documents accessible.
However, this is unfortunately not always possible.
If you are unable to read a document on our website using a screen reader or if you are unable to discern the colors of charts,
please send us an email.
We will contact you within a week.
And we will try to send you an accessible version within 4 weeks.
See also
- 02-12-2014 ACM closes investigation into AstraZeneca